Lotte Biologics to Participate in World ADC Asia and Bio USA

Full-scale Entry into the Global CDMO Market

On May 30, Lotte Biologics announced its plans to participate in a series of international bio events in June, both in Incheon and Boston, USA, to promote its competitiveness in the CDMO (Contract Development and Manufacturing Organization) sector.

Lotte Biologics 2025 Bio International Convention Booth Aerial View. Lotte Biologics

Lotte Biologics will first attend the "World ADC Asia Summit" held in Incheon from June 10 to 12, and then participate in the "2025 Bio International Convention (Bio USA)" in Boston, USA, from June 16 to 19 (local time).

"World ADC Asia" is the fourth edition of Asia's leading event dedicated to antibody-drug conjugates (ADC). The summit brings together a wide range of participants interested in ADCs to discuss the latest research and technological trends in development and manufacturing. At this event, Lotte Biologics aims to establish new business partnerships with potential clients in Asia and further solidify its position as a global CDMO.

Previously, at the JP Morgan Healthcare Conference in January, Lotte Biologics unveiled its proprietary and innovative ADC platform, Soluplex Link. In April, the company also achieved a milestone by signing an agreement with an Asia-based biotech firm to manufacture clinical trial candidate substances for ADCs.

"Bio USA" is the world's largest bio and pharmaceutical exhibition, organized by the Biotechnology Innovation Organization in the United States. It serves as a major networking platform where pharmaceutical and biotech professionals from around the world gather to discuss partnerships. Lotte Biologics will be participating in Bio USA for the fourth consecutive year since 2022.

The company will operate an exclusive exhibition booth to introduce itself to visitors. A "private meeting room" located at the back of the booth will be used for in-depth partnership discussions with global pharmaceutical companies and biotech ventures, as well as for meetings with visitors.

In particular, the company plans to showcase the operational launch of its ADC manufacturing facility at the Syracuse Bio Campus, along with a blueprint for the first plant at the Songdo Bio Campus, which is scheduled to begin commercial production in 2027. By highlighting the geographical advantage of its "dual-site" operation, Lotte Biologics intends to emphasize its ability to respond quickly and flexibly to client needs, its one-stop ADC service, and the quality competitiveness of the new Songdo Bio Campus currently under construction, thereby demonstrating its differentiated capabilities as a global CDMO.

A Lotte Biologics representative stated, "We will present concrete business strategies based on the synergy between the Syracuse Bio Campus and the Songdo Bio Campus to a diverse range of potential clients worldwide," adding, "By actively pursuing partnerships at international bio events, we will continue to strengthen our global competitiveness."